Gan & Lee(SH:603087) Sou Hu Cai Jing·2025-08-04 07:29Core Viewpoint - Gann Li Pharmaceutical Co., Ltd. has shown significant financial growth in the first quarter of 2025, with a notable increase in revenue and net profit, indicating strong operational performance and potential investment opportunities [1][2]. Financial Performance - As of the first quarter of 2025, Gann Li reported total revenue of 985 million yuan, representing a year-on-year growth of 75.76% [1]. - The company's net profit attributable to shareholders reached 312 million yuan, a year-on-year increase of 224.90% [1]. - The non-recurring net profit was 215 million yuan, showing a remarkable year-on-year growth of 1150.17% [1]. - The liquidity ratios are strong, with a current ratio of 4.917 and a quick ratio of 3.514, while the debt-to-asset ratio stands at 7.91% [1]. Market Activity - On August 4, 2025, Gann Li's stock closed at 63.26 yuan, up 3.72%, with a turnover rate of 4.55% and a trading volume of 255,400 hands, amounting to a transaction value of 1.579 billion yuan [1]. - The net inflow of main funds was 186 million yuan, accounting for 11.89% of the transaction value, with large orders contributing a net inflow of 112 million yuan [1]. Company Background - Gann Li Pharmaceutical Co., Ltd. was established in 1998 and is based in Beijing, primarily engaged in the pharmaceutical manufacturing industry [2]. - The company has a registered capital of 6.0106529 billion yuan and has made investments in six enterprises, participated in 2,427 bidding projects, and holds 190 trademark registrations and 103 patents [2].